Australian Clinical Labs Appoints Stephen Roche as New Board Chair

Australian Clinical Labs Ltd ( (AU:ACL) ) just unveiled an announcement.

Australian Clinical Labs Limited has announced the appointment of Stephen Roche as a new independent non-executive director, who will transition to the role of Chair of the Board by August 2025. Roche brings extensive strategic and operational experience from various sectors, including healthcare, retail, and consumer goods, which is expected to strengthen ACL’s board and support its mission of improving patient outcomes through innovative pathology services.

The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.25 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.

More about Australian Clinical Labs Ltd

Australian Clinical Labs (ACL) is a prominent private provider of pathology services in Australia. Their NATA accredited laboratories conduct a wide array of pathology tests for doctors, specialists, patients, hospitals, and corporate clients. ACL is recognized as one of the largest private hospital pathology businesses in the country, focusing on combining skilled personnel, medical and scientific leadership, and innovative technologies to enhance decision-making that saves and improves patients’ lives.

Average Trading Volume: 922,127

Technical Sentiment Signal: Sell

Current Market Cap: A$538.1M

See more data about ACL stock on TipRanks’ Stock Analysis page.